After a 5-year followup, the transcatheter aortic replacement (TAVR) with the self-expandable valve has offered clinical outcomes similar to surgical aortic valve replacement (SAVR) outcomes for intermediate risk patients. As we already knew form the 2-year followup, the all-cause or disabling stroke rate at 5 years between TAVR and SAVR continued to be similar (31.3%...
In CAD patients with diabetes the polymer-free amphilimus-eluting stent resulted non-inferior to the polymer-based zotarolimus-eluting Resolute Onyx. This new device, in addition to ultrathin struts, has already been found non-inferior to the Resolute Integrity in the general population at 3-year followup. Researchers believe that the new amphiphilic carrier might be especially useful in diabetic patients...
Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) will benefit from rivaroxaban monotherapy both in terms of safety and efficacy. The AFIRE study included 2215 patients with atrial fibrillation and stable coronary artery disease (CAD). A subgroups analysis recently published in JACC Intv evaluated patients undergoing coronary stenting. The study compared rivaroxaban + antiplatelet...
The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Now, this new analysis suggests that anatomic severity can predict events. However (surprisingly, once more), altering this severity through angioplasty does not change the prognosis...
Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history. This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used,...
According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a...
01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European...
During the virtual SOLACI-CACI 2021 Congress, the 11th ProEducar Fellows Course—SOLACI’s traditional activity aimed at expanding knowledge and providing didactic tools for all interventional trainees in Latin America—was held. The course was a huge success: almost 1500 people accessed the Andreas Gruentzig Virtual Room where the activity took place. Furthermore, over 35 prestigious speakers from all...
✔️ Day 3 Completo, SOLACI-CACI 2021 ✔️ Main Arena Auditorium 👨🏫 Program: 00:05 – CBS@SOLACI-CACI Session 01:43:26 – CCI@SOLACI-CACI Session 03:07:38 – Oral presentation – Structural III 04:32:21 – Oral presentation – Coronary III 06:01:39 – SAC FAC@SOLACI-CACI Session 👉 SESSION I: Functional Mitral Regurgitation: New Horizons for Transcatheter Therapy 👉 SESSION II: Medical Treatment...
✔️ Watch again the complete SAC-FAC Session in the SOLACI-CACI 2021 Congress. 👨🏫 Program: – SESSION I: Functional Mitral Regurgitation: New Horizons for Transcatheter Therapy 01:06 – Optimal Medical Treatment in Patients with Cardiac Failure and Mitral Regurgitation – Florencia Renedo 12:12 – Ultrasonographic Screening of Patients for Endovascular Therapy – Walter García 25:43 –...